DK2627375T3 - Dosisindstillingsmekanisme og fremgangsmåde til indstilling af en dosis - Google Patents
Dosisindstillingsmekanisme og fremgangsmåde til indstilling af en dosis Download PDFInfo
- Publication number
- DK2627375T3 DK2627375T3 DK11767445.7T DK11767445T DK2627375T3 DK 2627375 T3 DK2627375 T3 DK 2627375T3 DK 11767445 T DK11767445 T DK 11767445T DK 2627375 T3 DK2627375 T3 DK 2627375T3
- Authority
- DK
- Denmark
- Prior art keywords
- dose
- clutch
- housing
- blocker
- coupling
- Prior art date
Links
- 230000007246 mechanism Effects 0.000 title claims description 84
- 238000000034 method Methods 0.000 title claims description 9
- 239000003814 drug Substances 0.000 claims description 43
- 238000012377 drug delivery Methods 0.000 claims description 38
- 238000010168 coupling process Methods 0.000 claims description 24
- 238000005859 coupling reaction Methods 0.000 claims description 24
- 230000009977 dual effect Effects 0.000 claims description 20
- 230000008878 coupling Effects 0.000 claims description 19
- 230000037452 priming Effects 0.000 claims description 9
- 230000004323 axial length Effects 0.000 claims 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 41
- 238000002347 injection Methods 0.000 description 23
- 239000007924 injection Substances 0.000 description 23
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 22
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 21
- 102000004877 Insulin Human genes 0.000 description 19
- 108090001061 Insulin Proteins 0.000 description 19
- 229940125396 insulin Drugs 0.000 description 17
- 108010092217 Long-Acting Insulin Proteins 0.000 description 15
- 229940100066 Long-acting insulin Drugs 0.000 description 15
- 229940079593 drug Drugs 0.000 description 15
- 239000000203 mixture Substances 0.000 description 14
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 13
- 102000016261 Long-Acting Insulin Human genes 0.000 description 13
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 11
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 10
- 238000013461 design Methods 0.000 description 9
- 230000000903 blocking effect Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 108010026951 Short-Acting Insulin Proteins 0.000 description 5
- 229940123452 Rapid-acting insulin Drugs 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 101000579646 Penaeus vannamei Penaeidin-1 Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 239000004026 insulin derivative Substances 0.000 description 3
- 229940126601 medicinal product Drugs 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 108010011459 Exenatide Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000579647 Penaeus vannamei Penaeidin-2a Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229940125388 beta agonist Drugs 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 229960001519 exenatide Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 description 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 108010019598 Liraglutide Proteins 0.000 description 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 description 1
- 108010058003 Proglucagon Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- 229940123958 Short-acting insulin Drugs 0.000 description 1
- 108010010056 Terlipressin Proteins 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- 206010057362 Underdose Diseases 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229960003060 bambuterol Drugs 0.000 description 1
- ANZXOIAKUNOVQU-UHFFFAOYSA-N bambuterol Chemical compound CN(C)C(=O)OC1=CC(OC(=O)N(C)C)=CC(C(O)CNC(C)(C)C)=C1 ANZXOIAKUNOVQU-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000585 bitolterol mesylate Drugs 0.000 description 1
- HODFCFXCOMKRCG-UHFFFAOYSA-N bitolterol mesylate Chemical compound CS([O-])(=O)=O.C1=CC(C)=CC=C1C(=O)OC1=CC=C(C(O)C[NH2+]C(C)(C)C)C=C1OC(=O)C1=CC=C(C)C=C1 HODFCFXCOMKRCG-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 1
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 1
- 229960001117 clenbuterol Drugs 0.000 description 1
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 210000003158 enteroendocrine cell Anatomy 0.000 description 1
- 108010015174 exendin 3 Proteins 0.000 description 1
- LMHMJYMCGJNXRS-IOPUOMRJSA-N exendin-3 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@H](C)O)[C@H](C)O)C(C)C)C1=CC=CC=C1 LMHMJYMCGJNXRS-IOPUOMRJSA-N 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- 229960001442 gonadorelin Drugs 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229960004078 indacaterol Drugs 0.000 description 1
- QZZUEBNBZAPZLX-QFIPXVFZSA-N indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 description 1
- 229940025708 injectable product Drugs 0.000 description 1
- -1 insulin Chemical class 0.000 description 1
- 229940127560 insulin pen Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229950008204 levosalbutamol Drugs 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- 108010004367 lixisenatide Proteins 0.000 description 1
- 229960001093 lixisenatide Drugs 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- 229960002333 nafarelin Drugs 0.000 description 1
- 229960002657 orciprenaline Drugs 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229960005414 pirbuterol Drugs 0.000 description 1
- 229960002288 procaterol Drugs 0.000 description 1
- FKNXQNWAXFXVNW-BLLLJJGKSA-N procaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)[C@@H](NC(C)C)CC FKNXQNWAXFXVNW-BLLLJJGKSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229960004532 somatropin Drugs 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 229960003813 terlipressin Drugs 0.000 description 1
- BENFXAYNYRLAIU-QSVFAHTRSA-N terlipressin Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC1 BENFXAYNYRLAIU-QSVFAHTRSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31533—Dosing mechanisms, i.e. setting a dose
- A61M5/31535—Means improving security or handling thereof, e.g. blocking means, means preventing insufficient dosing, means allowing correction of overset dose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31525—Dosing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31533—Dosing mechanisms, i.e. setting a dose
- A61M5/31545—Setting modes for dosing
- A61M5/31548—Mechanically operated dose setting member
- A61M5/3155—Mechanically operated dose setting member by rotational movement of dose setting member, e.g. during setting or filling of a syringe
- A61M5/31551—Mechanically operated dose setting member by rotational movement of dose setting member, e.g. during setting or filling of a syringe including axial movement of dose setting member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
- A61M5/31576—Constructional features or modes of drive mechanisms for piston rods
- A61M5/31583—Constructional features or modes of drive mechanisms for piston rods based on rotational translation, i.e. movement of piston rod is caused by relative rotation between the user activated actuator and the piston rod
- A61M5/31585—Constructional features or modes of drive mechanisms for piston rods based on rotational translation, i.e. movement of piston rod is caused by relative rotation between the user activated actuator and the piston rod performed by axially moving actuator, e.g. an injection button
Landscapes
- Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Claims (14)
1. Dosisindstillingsmekanisme til en medikamentafgivelsesindretning, hvor mekanismen omfatter: et medikamentafgivelsesindretningshus (250); en dosisindstillingsknapmekanisme (204), der er anbragt i det mindste delvist i huset og er drejelig under dosisindstilling og dosisafgivelse, et koblingselement (208), der er drejeligt under dosisindstilling og ikke-drejeligt under dosisafgivelse; kendetegnet ved i det mindste et dobbelttilstandsspor (262) inden i huset (250), der er aksialt og drejeligt fastgjort i forhold til huset, som omfatter et første spor (264), et andet spor (266) og et tredje spor (268); en koblingsplade (212), der er drejeligt fastgjort i forhold til huset; og en koblingsblokker (220), der er i gevindindgreb med koblingspladen (212) og har i det mindste en radial kile (222), der er i indgreb med det i det mindste ene dobbelttilstandsspor (262), hvor den radiale kile (222) er i indgreb med det første spor (264) under dosisindstilling, indtil en forudbestemt minimal dosis er valgt med dosisindstillingsknapmekanismen (204) , og med det andet spor (266), efter en forudbestemt minimal dosis er valgt med dosisindstillingsknapmekanismen (204) .
2. Mekanisme ifølge krav 1, der yderligere omfatter et forspændingselement (216), der er anbragt mellem koblingsblokkeren (220) og koblingspladen (212).
3. Mekanisme ifølge kravene 1 eller 2, hvor koblingsblokkeren (220) omfatter en distal ende, og koblingspladen (212) omfatter en proksimal ende, hvor den distale ende af koblingsblokkeren (220) er adskilt fra den proksimale ende af koblingspladen (212) med en afstand D under dosisindstilling og med en afstand, der er mindre end D under dosisafgivelse.
4. Mekanisme ifølge et hvilket som helst af de foregående krav, hvor koblingspladen (212) har i det mindste en radial kile (214), der er notet til huset (260) for at forhindre drejning under dosisindstilling og dosisafgivelse.
5. Mekanisme ifølge et hvilket som helst af de foregående krav, hvor koblingsblokkeren (220) og koblingspladen (212) er konfigureret til at forhindre afgivelse af en dosis, når en indstillet dosis er mindre end en forudbestemt minimal dosis.
6. Mekanisme ifølge krav 5, hvor koblingsblokkeren (220) og koblingspladen (212) er konfigureret til at forhindre afgivelse af dosisen, når den indstillede dosis er mindre end den forudbestemte minimale dosis, men tillader afgivelsen af den indstillede dosis, hvis den indstillede dosis er mindre end en forudbestemt maksimal priming dosis.
7. Mekanisme ifølge et hvilket som helst af de foregående krav, hvor dobbelttilstandssporet (262) har en aksial længde, som er proportional med en forudbestemt minimal dosis.
8. Mekanisme ifølge et hvilket som helst af de foregående krav, der yderligere omfatter et fjerde spor (274), hvor koblingsblokkerkilen (222) er i indgreb med det fjerde spor (274), når en dosis fra nul til en forudbestemt maksimal priming dosis er valgt.
9. Mekanisme ifølge et hvilket som helst af de foregående krav, hvor dobbelttilstandssporet (262), koblingspladen (212) og koblingsblokkeren (220) er konfigureret til at forhindre en relativ aksial bevægelse og/eller en relativ drejelig bevægelse mellem koblingspladen (212) og koblingsblokkeren (220), når en indstillet dosis er mindre end en forudbestemt minimal dosis.
10. Mekanisme ifølge et hvilket som helst af de foregående krav, hvor koblingspladen (212) er en muffelignende eller ringlignende komponent, der omfatter et middel (214) til drejelig kobling af koblingspladen (212) til koblingselementet (208) .
11. Mekanisme ifølge et hvilket som helst af de foregående krav, hvor koblingsblokkeren (220) er en muffelignende komponent, der i det mindste delvist er omgivet af koblingspladen (212).
12. Mekanisme ifølge et hvilket som helst af de foregående krav, der yderligere omfatter en drivmuffe (224), der er drejelig under dosisindstilling og aksialt forskydelig under dosisafgivelse.
13. Mekanisme ifølge krav 12, hvor drivmuffen (224) er drejeligt låst til koblingselementet (208), og hvor drivmuffen (224) omfatter et middel, der understøtter koblingsblokkeren (220) i den distale retning.
14. Fremgangsmåde til indstilling af i det mindste en forudbestemt minimal dosis af et medikament, der omfatter trinene til tilvejebringelse af et medikamentafgivelsesindretningshus (250); aksial og drejelig fastgørelse af et dobbelttilstandsspor (262) inden i huset (250) med hensyn til huset, hvor dobbelttilstandssporet (262) omfatter et første spor (264) , et andet spor (266) og et tredje spor (268); anbringelse af en dosisindstillingsknapmekanisme (204) i det mindste delvist i huset (250), hvor dosisindstillingsknapmekanismen er drejelig under dosisindstilling og dosisafgivelse; tilvejebringelse af et koblingselement (208), der er drejeligt under dosisindstilling og ikke-drejeligt under dosisafgivelse; drejelig fastgørelse af en koblingsplade (212) i forhold til huset (250); bringe en koblingsblokker (220) i indgreb med koblingspladen (212) ved hjælp af et gevind (226); og bringe en radial kile (222) på koblingsblokkeren (220) i indgreb med dobbelttilstandssporet (262), hvor den radiale kile (222) løber i det første spor (264), indtil en forudbestemt minimal dosis er blevet valgt.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39274510P | 2010-10-13 | 2010-10-13 | |
| EP11168188 | 2011-05-31 | ||
| PCT/EP2011/067676 WO2012049139A1 (en) | 2010-10-13 | 2011-10-11 | Dose setting mechanism and method of setting a dose |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2627375T3 true DK2627375T3 (da) | 2016-01-04 |
Family
ID=44453856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11767445.7T DK2627375T3 (da) | 2010-10-13 | 2011-10-11 | Dosisindstillingsmekanisme og fremgangsmåde til indstilling af en dosis |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9517308B2 (da) |
| EP (1) | EP2627375B1 (da) |
| JP (1) | JP5894169B2 (da) |
| CN (1) | CN103260674B (da) |
| AR (1) | AR083386A1 (da) |
| AU (1) | AU2011315624B2 (da) |
| BR (1) | BR112013009080A2 (da) |
| CA (1) | CA2826855A1 (da) |
| DK (1) | DK2627375T3 (da) |
| IL (1) | IL225678A (da) |
| TW (1) | TWI554302B (da) |
| WO (1) | WO2012049139A1 (da) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105102030A (zh) | 2013-04-10 | 2015-11-25 | 赛诺菲 | 注射装置 |
| HK1214994A1 (zh) * | 2013-04-10 | 2016-08-12 | Sanofi | 注射装置 |
| RU2015146767A (ru) * | 2013-04-10 | 2017-05-12 | Санофи | Инъекционное устройство |
| BR112015024952A2 (pt) * | 2013-04-10 | 2017-07-18 | Sanofi Sa | dispositivo injetor |
| BR112015025703A2 (pt) * | 2013-04-10 | 2017-07-18 | Sanofi Sa | dispositivo de injeção |
| US10137251B2 (en) * | 2013-05-27 | 2018-11-27 | Sanofi-Aventis Deutschland Gmbh | Assembly for a drug delivery device and drug delivery device |
| GB201318817D0 (en) * | 2013-10-24 | 2013-12-11 | Owen Mumford Ltd | Injection Devices |
| JP6422969B2 (ja) * | 2013-11-15 | 2018-11-14 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 薬物送達デバイス用のアセンブリおよび薬物送達デバイス |
| JP6566946B2 (ja) | 2013-11-22 | 2019-08-28 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 偽造防止機能を有する薬物送達デバイス |
| DK3148618T3 (da) * | 2014-05-28 | 2019-05-06 | Sanofi Aventis Deutschland | Lægemiddeladministrationsanordning til administration af to medikamenter |
| TW201611853A (en) * | 2014-07-01 | 2016-04-01 | Sanofi Sa | Injection device |
| EP3006068B1 (en) * | 2014-10-09 | 2020-12-09 | Ypsomed AG | Medication dispensing apparatus with sub dose prevention |
| CN104491956B (zh) * | 2014-12-30 | 2017-03-08 | 江苏德尔福医疗器械有限公司 | 一种注射笔 |
| WO2016128424A1 (en) * | 2015-02-10 | 2016-08-18 | Sanofi-Aventis Deutschland Gmbh | Drive mechanism for an injection device |
| EP3256195B1 (en) * | 2015-02-10 | 2021-09-22 | Sanofi-Aventis Deutschland GmbH | Drive mechanism for an injection device |
| DK3261689T3 (da) * | 2015-02-27 | 2019-05-27 | Novo Nordisk As | Lægemiddelleveringsindretning med dosisgenindstillingsmekanisme |
| JP2018516119A (ja) * | 2015-05-28 | 2018-06-21 | ノボ・ノルデイスク・エー／エス | 多機能バイアス構造体を有する薬剤送達装置 |
| EP3181169A1 (en) * | 2015-12-14 | 2017-06-21 | Sanofi-Aventis Deutschland GmbH | Drive mechanism for an injection device |
| EP3181171A1 (en) * | 2015-12-14 | 2017-06-21 | Sanofi-Aventis Deutschland GmbH | Drive mechanism for an injection device |
| JP6963573B2 (ja) * | 2016-07-01 | 2021-11-10 | サノフイSanofi | 薬物送達デバイス |
| DK3668577T3 (da) | 2017-02-16 | 2023-11-13 | Sanofi Sa | Drivmekanisme til en injektionsanordning |
| WO2020082260A1 (zh) * | 2018-10-24 | 2020-04-30 | 群康生技股份有限公司 | 具有注射剂量调整功能的注射器 |
| CN114901333A (zh) * | 2019-12-27 | 2022-08-12 | 赛诺菲 | 用于检测对注射装置的操纵的设备 |
| CN119136864A (zh) | 2022-04-21 | 2024-12-13 | 赛诺菲 | 用于注射装置的驱动机构 |
| TWI846497B (zh) * | 2023-05-31 | 2024-06-21 | 群康生技股份有限公司 | 具有調整注射劑量功能的注射機構及注射器 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5827232A (en) * | 1994-06-22 | 1998-10-27 | Becton Dickinson And Company | Quick connect medication delivery pen |
| US6277099B1 (en) * | 1999-08-06 | 2001-08-21 | Becton, Dickinson And Company | Medication delivery pen |
| DE10106368B4 (de) * | 2001-02-12 | 2006-02-02 | Tecpharma Licensing Ag | Verstellsperre für eine Vorrichtung zur Verabreichung einer einstellbaren Dosis eines injizierbaren Produkts |
| GB0304822D0 (en) * | 2003-03-03 | 2003-04-09 | Dca Internat Ltd | Improvements in and relating to a pen-type injector |
| GB0304823D0 (en) * | 2003-03-03 | 2003-04-09 | Dca Internat Ltd | Improvements in and relating to a pen-type injector |
| EP1831809A2 (en) | 2004-12-08 | 2007-09-12 | Novo Nordisk A/S | Device for displaying data relevant for a diabetic patient |
| PL1877119T3 (pl) | 2005-01-25 | 2019-03-29 | Novo Nordisk A/S | Urządzenie do wstrzykiwania z mechanizmem zwrotnym informującym o końcu dawki |
| DE102005023823B4 (de) * | 2005-05-24 | 2022-11-17 | Tecpharma Licensing Ag | Dosiervorrichtung für eine Injektionsvorrichtung und Injektionsvorrichtung mit einer solchen Dosiervorrichtung |
| DE102005060929A1 (de) | 2005-09-14 | 2007-03-15 | Tecpharma Licensing Ag | Injektionsvorrichtung mit Zweiwege-Rutschkupplung |
| GB0700754D0 (en) | 2007-01-15 | 2007-02-21 | Oxford Instr Analytical Ltd | Charged particle analyser and method |
| WO2009097934A1 (en) | 2008-02-05 | 2009-08-13 | Shl Group Ab | Injection device with pre-activation means |
| EP2351591A1 (en) | 2010-02-02 | 2011-08-03 | Sanofi-Aventis Deutschland GmbH | Assembly for a drug delivery device and drug delivery device |
-
2011
- 2011-10-11 DK DK11767445.7T patent/DK2627375T3/da active
- 2011-10-11 WO PCT/EP2011/067676 patent/WO2012049139A1/en not_active Ceased
- 2011-10-11 US US13/878,762 patent/US9517308B2/en not_active Expired - Fee Related
- 2011-10-11 AU AU2011315624A patent/AU2011315624B2/en not_active Ceased
- 2011-10-11 BR BR112013009080A patent/BR112013009080A2/pt not_active IP Right Cessation
- 2011-10-11 JP JP2013533169A patent/JP5894169B2/ja not_active Expired - Fee Related
- 2011-10-11 EP EP11767445.7A patent/EP2627375B1/en not_active Not-in-force
- 2011-10-11 TW TW100136651A patent/TWI554302B/zh not_active IP Right Cessation
- 2011-10-11 CA CA2826855A patent/CA2826855A1/en not_active Abandoned
- 2011-10-11 CN CN201180059706.XA patent/CN103260674B/zh not_active Expired - Fee Related
- 2011-10-12 AR ARP110103763A patent/AR083386A1/es not_active Application Discontinuation
-
2013
- 2013-04-10 IL IL225678A patent/IL225678A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP2627375B1 (en) | 2015-09-30 |
| TWI554302B (zh) | 2016-10-21 |
| CA2826855A1 (en) | 2012-04-19 |
| CN103260674B (zh) | 2015-06-10 |
| BR112013009080A2 (pt) | 2016-07-19 |
| IL225678A (en) | 2016-07-31 |
| JP5894169B2 (ja) | 2016-03-23 |
| AR083386A1 (es) | 2013-02-21 |
| AU2011315624A1 (en) | 2013-04-18 |
| WO2012049139A1 (en) | 2012-04-19 |
| CN103260674A (zh) | 2013-08-21 |
| AU2011315624B2 (en) | 2015-01-29 |
| US9517308B2 (en) | 2016-12-13 |
| IL225678A0 (en) | 2013-06-27 |
| EP2627375A1 (en) | 2013-08-21 |
| US20130296802A1 (en) | 2013-11-07 |
| JP2013539695A (ja) | 2013-10-28 |
| HK1184722A1 (en) | 2014-01-30 |
| TW201217026A (en) | 2012-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2627375T3 (da) | Dosisindstillingsmekanisme og fremgangsmåde til indstilling af en dosis | |
| DK2627380T3 (da) | Dosisindstillingsmekanisme og fremgangsmåde til indstilling af en dosis | |
| EP2627377B1 (en) | Dose setting mechanism and method of using same | |
| EP2627379B1 (en) | Drug delivery device with a dose setting mechanism and method of using same | |
| EP2627378B1 (en) | Dose setting mechanism for a drug delivery device | |
| HK1184722B (en) | Dose setting mechanism and method of setting a dose | |
| HK1184720B (en) | Drug delivery device with a dose setting mechanism and method of using same | |
| HK1184720A (en) | Drug delivery device with a dose setting mechanism and method of using same | |
| HK1184086B (en) | Dose setting mechanism for a drug delivery device | |
| HK1184086A (en) | Dose setting mechanism for a drug delivery device | |
| HK1185294B (en) | Dose setting mechanism and method of using same | |
| HK1185294A (en) | Dose setting mechanism and method of using same | |
| HK1183254B (en) | Dose setting mechanism and method of setting a dose |